| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 42,625 | 42,715 | 02.04. | |
| 42,325 | 42,755 | 02.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 650,00 | 4 | |||
| 170,00 | 8 | |||
| 135,00 | 57 | |||
| 60,00 | 15 | |||
| 52,20 | 500 | |||
| 51,76 | 50 | |||
| 44,405 | 44 | |||
| 44,175 | 197 | |||
| 44,165 | 184 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 197 | 44,045 | |||
| 197 | 44,035 | |||
| 184 | 44,030 | |||
| 197 | 44,015 | |||
| 197 | 43,965 | |||
| 197 | 43,905 | |||
| 44 | 43,810 | |||
| 37 | 36,000 | |||
| 120 | 20,800 | |||
| 1.052 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.422 | 0,437 | 1.059 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:46:09 | 42,600 | 9 |
| 15:46:09 | 42,600 | 91 |
| 15:44:21 | 42,540 | 31 |
| 15:41:43 | 42,445 | 125 |
| 15:37:20 | 42,185 | 19 |
| 15:31:08 | 42,045 | 70 |
| 15:28:01 | 42,200 | 19 |
| 15:25:00 | 42,185 | 69 |
| 15:25:00 | 42,140 | 33 |
| 15:25:00 | 42,140 | 125 |
| 15:18:18 | 42,200 | 51 |
| 15:18:18 | 42,205 | 73 |
| 15:18:18 | 42,205 | 124 |
| 14:31:22 | 42,350 | 6 |
| 14:31:16 | 42,540 | 5 |
| 14:11:07 | 42,420 | 14 |
| 14:02:54 | 42,330 | 75 |
| 14:02:54 | 42,330 | 250 |
| 14:02:54 | 42,330 | 125 |
| 14:02:54 | 42,350 | 2 |
| Tagesumsatz Xetra | -1,205 -2,76 % | 9.035 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Mo | Moderna vor entscheidender Bewährungsprobe | 609 | LYNX Broker | Moderna steht derzeit wieder stärker im Fokus technischer Beobachter. Im Chartbild zeigen sich Hinweise auf eine Stabilisierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| 27.03. | MODERNA INC: Stabilität als strategisches Signal | 23 | Maximilian Berger | ||
| 27.03. | ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? | 44 | Zacks | ||
| 25.03. | Moderna Stock is Soaring. Is It Too Late to Buy? | 23 | The Motley Fool | ||
| 24.03. | Moderna stands as the best performing large-cap healthcare stock YTD | 19 | Seeking Alpha |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Do | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| Do | Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights | Business Wire | Regulatory News:
Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.
2025 business... ► Artikel lesen | |
| Do | Resverlogix Corp.: Resverlogix Corp. Announces Issuance of MCTO by ASC | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the... ► Artikel lesen | |
| Do | Dermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System | ACCESS Newswire | - This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia... ► Artikel lesen | |
| Do | Context Therapeutics Inc.: Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer | GlobeNewswire (Europe) | Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02,... ► Artikel lesen |